JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265192

Human IP6K2 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

IP6K2 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Sanger Sequencing - Human IP6K2 knockout HeLa cell line (AB265192)
  • Sanger seq

Unknown

Sanger Sequencing - Human IP6K2 knockout HeLa cell line (AB265192)

Homozygous : 1 bp insertion in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265192-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265192 Human IP6K2 knockout HeLa cell line", "number":"AB265192-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265192-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265192-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265192 Human IP6K2 knockout HeLa cell line", "number":"AB265192-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265192-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265192-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265192 Human IP6K2 knockout HeLa cell line", "number":"AB265192-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265192-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265192 Human IP6K2 knockout HeLa cell line", "number":"AB265192-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
IP6K2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The IP6K2 protein also known as inositol hexakisphosphate kinase 2 functions mechanically as an enzyme that converts inositol hexakisphosphate (IP6) into diphosphoinositol pentakisphosphate (IP7). It has a molecular mass of about 55 kDa. This kinase is widely expressed in various tissues with significant levels found in the brain and testes. IP6K2 activity plays a role in cellular energy homeostasis and signaling.
Biological function summary

IP6K2 influences several cellular processes including apoptosis and cell cycle regulation. It operates as a part of protein complexes that mediate the synthesis of inositol pyrophosphates which are important secondary messengers in cells. Through these roles IP6K2 helps regulate physiological functions such as insulin signaling and energy balance. Its interactions with various binding partners also enable it to influence cell survival and growth parameters.

Pathways

IP6K2 is actively involved in the inositol phosphate metabolism and apoptosis pathways. Inositol phosphate metabolism involves a range of signaling molecules where IP6K2 contributes to the generation of key signaling lipids. It works in conjunction with other kinases such as IP6K1 and phosphatidylinositol 3-kinase (PI3K) facilitating complex cellular activities. Through these pathways IP6K2 modulates processes that are essential for maintaining cell viability and proper cellular responses to external stimuli.

Dysregulation of IP6K2 has associations with several conditions including cancer and metabolic disorders. Altered IP6K2 function can influence cancer development by affecting apoptotic pathways where it interacts with key proteins such as p53 to regulate cell death. In metabolic disorders the kinase's role in insulin signaling connects it to metabolic issues like type 2 diabetes as its involvement in signal transduction impacts glucose homeostasis and insulin sensitivity.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com